RB 201
Alternative Names: RB-201; RB-201™ Bispecific ADC; YH-012Latest Information Update: 30 Jul 2024
At a glance
- Originator Beijing Biocytogen
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Jul 2024 Radiance Biopharma announces intention to submit an Investigational New Drug (IND) application in Q1 2025 (Radiance Biopharma pipeline, July 2024)
- 17 Jan 2024 Radiance Bio plans a first-in-human phase Ia/b trial in solid tumours expressing HER2 and TROP-2 (Radiance Bio pipeline, January 2024)
- 08 Jan 2024 Biocytogen Pharmaceuticals and Radiance Biopharma enter into an option and license agreement for YH 012 .